Pharmaceutical company Neuraxpharm Group reported on Wednesday the formation of Neuraxpharm Portugal in Lisbon, expanding its operations in Southern Europe.
Neuraxpharm Portugal will be part of the company's Southern European Region that comprises Italy, Spain and now Portugal.
Through the new subsidiary, Neuraxpharm will leverage its industry networks and central nervous system (CNS) expertise to make its extensive portfolio available to patients. It is planning the first commercial launch in December this year with a probiotic product.
The company aims to build its position as a CNS specialist in Portugal offering its wide portfolio of branded and consumer healthcare products in the Portuguese market.
Javier Mercadé, the general manager of Italy and Spain, was appointed as head of Southern Region earlier this year and Teng Dias has been named as commercial director of the Neuraxpharm Portugal business.
Hikma announces Health Canada approval of KLOXXADO Nasal Spray for opioid overdose treatment
Plus Therapeutics secures FDA Orphan Drug Designation for Rhenium (186Re) Obisbemeda
Latigo Biotherapeutics' LTG-001 receives US FDA Fast Track designation
GenSight Biologics reports positive five-year resultsfor LUMEVOQ gene therapy
Bain Capital to acquire Mitsubishi Tanabe Pharma in USD3.3bn deal
Innovent and ASK Pharm's limertinib NDA receives Chinese regulatory approval
Anavex reports positive long-term data for blarcamesine in early Alzheimer's disease
Johnson & Johnson agrees acquisition of Intra-Cellular Therapies Inc
Neuraxpharm acquires Provigil and Nuvigil to expand CNS portfolio
Nuvation Bio secures NMPA approval for taletrectinib in China
JCR Pharmaceuticals and Modalis Therapeutics advance to next phase of joint gene therapy research
PTC Therapeutics submits vatiquinone NDA to US FDA
Mitsubishi Tanabe Pharma forms research collaboration with Dewpoint Therapeutics
IXICO signs commercial agreement with PETNET Solutions to enhance neuroimaging capabilities